Comparative access pathways: Oregon, Canada and Australia

Context in 2026

Access pathways are now being tested through distinct policy instruments: service regulation in Oregon, special access mechanisms in Canada, and prescribing governance frameworks in Australia.

These pathways show that access is not a single event; it is a sequence of policy, operational and equity decisions that determine who can actually receive care.

Key findings

• Different legal and regulatory instruments can support access when governance and safety roles are clear.

• Operational design choices strongly influence affordability, geography and equity outcomes.

• Policy models can be compared for transferable mechanisms without assuming direct copy-paste adoption.

Implications for implementation teams

• Design access models with explicit equity indicators from first deployment.

• Track operational constraints alongside clinical outcomes in post-launch monitoring.

• Use comparative pathway learning to strengthen local commissioning and rollout decisions.

Sources

• Oregon Psilocybin Services (Oregon Health Authority, 2023-01-02)

• Special Access Program for Drugs (Health Canada, 2026-04-08)

• Checklist for Prescribing Psychiatrists of Psychedelics (Therapeutic Goods Administration (TGA), 2023-09-01)

• PsyPal Guidance Paper (Version 5) (PsyPal Consortium, 2026-03-26)